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• ADCT-402 is a novel CD19-targeted ADC delivering SG3199, a highly cytotoxic DNA 
minor groove interstrand cross-linking PBD dimer warhead 
 
• ADCT-402 has potent and selective anti-tumor activity against CD19-expressing 




Human CD19 antigen is a 95-kDa type I membrane glycoprotein in the immunoglobulin 
superfamily whose expression is limited to the various stages of B-cell development and 
differentiation and is maintained in the majority of B-cell malignancies, including leukemias 
and non-Hodgkin lymphomas of B-cell origin. Coupled with its differential and favourable 
expression profile, CD19 has rapid internalization kinetics and it is not shed into the 
circulation, making it an ideal target for the development of antibody-drug conjugates (ADCs) 
to treat B-cell malignancies.  
ADCT-402 (loncastuximab tesirine) is a novel CD19-targeted ADC delivering SG3199, a 
highly cytotoxic DNA minor groove interstrand cross-linking pyrrolobenzodiazepine (PBD) 
dimer warhead. It showed potent and highly targeted in vitro cytotoxicity in CD19-expressing 
human cell lines. ADCT-402 was specifically bound, internalized and trafficked to lysosomes 
in CD19-expressing cells and following release of warhead, resulted in formation of DNA 
cross-links which persisted for 36 h. Bystander killing of CD19-negative cells by ADCT-402 
was also observed. In vivo, single doses of ADCT-402 resulted in highly potent, dose-
dependent anti-tumor activity in several subcutaneous and disseminated human tumor 
models with marked superiority to comparator ADCs delivering tubulin inhibitors. Dose-
dependent DNA cross-links and γ-H2AX DNA damage response were measured in tumors 
by 24 h after single dose administration, while matched PBMCs showed no evidence of DNA 
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damage. Pharmacokinetic analysis in rat and cynomolgus monkey showed excellent stability 
and tolerability of ADCT-402 in vivo.  
Together, these impressive data were used to support the clinical testing of this novel ADC 
in patients with CD19-expressing B-cell malignancies. 
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INTRODUCTION 
Human CD19 antigen is a 95-kDa type I membrane glycoprotein belonging to the 
immunoglobulin superfamily1. In normal human tissue, CD19 expression is restricted to the 
various stages of B-cell development and differentiation (except hematological stem cells 
and plasma cells)2,3 and its expression is maintained in the majority of B-cell malignancies, 
including leukemias and non-Hodgkin lymphomas (NHL) of B-cell origin4. 
Because of its widespread expression, CD19 is an attractive therapeutic target and several 
antibody-based therapies are in clinical development5. A bispecific scFv anti-CD19/anti-CD3 
bispecific T-cell engager blinatumomab (Blincyto™) is approved for the treatment of second-
line Philadelphia chromosome-negative relapsed or refractory (R/R) acute lymphoblastic 
leukemia6. CD19 also remains the most investigated target for CAR T-cell therapy7. 
CD19 has rapid internalization kinetics8,9 and it is not shed into the circulation10. These 
features, coupled with its differential and favourable expression profile, make CD19 an ideal 
target for the development of antibody-drug conjugates (ADCs) to treat B-cell malignancies. 
Indeed, anti-CD19 auristatin containing ADC denintuzumab mafodotin (SGN-CD19A)11 and 
maytansinoid-containing coltuximab ravtansine (SAR3419)12 have been investigated in the 
clinic. 
As an alternative to the delivery of tubulin binding-based warheads, novel ADCs delivering 
highly cytotoxic pyrrolobenzodiazepine (PBD) dimers have been developed13-15. PBD dimers 
are a class of exquisitely potent DNA minor groove interstrand cross-linking agents16; one of 
which, SG2000 (SJG-136) has shown activity against both solid tumor and haematological 
malignancies17,18. Advantages over ADCs employing other warheads including tubulin 
inhibitors (e.g. auristatins and maytansinoids), DNA cleavage agents (e.g. calicheamicin) 
and classical chemotherapeutics, include the ability to target low copy number antigens and 
tumor-initiating cells14, and to exploit low drug-antibody ratios (DARs). Because of their novel 
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mechanism of action, PBD-containing ADCs are active in tumors inherently resistant to other 
warhead types and against multidrug-resistant cancers13.  
PBD dimer SG319919 is the released warhead component of the ADC payload tesirine 
(SG3249)20, currently being evaluated clinically in several ADCs including ADCT-301, 
ADCT-502, MEDI3726 and rovalpituzumab tesirine (Rova-T) for which Phase I data in small 
cell lung cancer has been reported21, and which is currently in several Phase II and Phase III 
studies. 
Here, we report the preclinical evaluation of the novel anti-CD19 ADC ADCT-402 
(loncastuximab tesirine) containing the PBD dimer payload tesirine. On the basis of these 
impressive pre-clinical data, this agent is currently being evaluated in Phase I studies of both 
R/R NHL and R/R B-ALL.  
 
METHODS 
Synthesis of ADCs 
RB4v1.2 antibody was conjugated to tesirine essentially as previously described15.  The 
ADC was formulated in 30 mM histidine, 200 mM sorbitol, 0.02% Tween-20, pH 6.0. The 
solution was filtered (0.22 μm) and stored at -70°C.  
ADCs RB4v1.2-DM4 and hBU12-mc-MMAF were generated by Concortis (San Diego, USA) 
as described in 22 and in patent US 8,242,252 B2, respectively. 
Characterisation of ADCT-402 by SEC, HIC and RPLC 
Characterisation of synthesised ADCT-402 was performed by size exclusion 
chromatography (SEC), hydrophobic interaction chromatography (HIC) and reduced reverse 
phase liquid chromatography (RPLC), as previously described15.  
Human cell lines 
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The source of cell lines used in this study along with cell growth media are shown in 
Supplementary Table S1.  
CD19 cell surface density 
Cell surface CD19 density was determined using Bangs Laboratory Quantum Simply 
Cellular Anti-human IgG beads according to the manufacturer’s instructions. 
In vitro cell killing and bystander assay 
Cell lines were incubated in growth medium with serial dilutions of ADCT-402, the isotype 
control ADC, or the free warhead SG3199 for 5 days at 37 °C in a 5% CO2-gassed, 
humidified incubator.  Cell viability was measured with CellTiter 96® AQueous One Solution 
Cell Proliferation (Promega) according to manufacturer’s instructions. The data were 
normalised to vehicle-treated cells. IC50 values were determined by using GraphPad 
software (GraphPad, San Diego, CA). The mean and standard errors of the means of three 
independent IC50 values were determined.  
For the bystander assay, Ramos or NCI-N87 cells were incubated for the indicated time 
points with ADCT-402. Condition medium was transferred to Karpas-299 cells, incubated for 
4 days and cell viability measured. 
Internalization studies 
Cells were exposed to ADCT-402 for 1 h at 4˚C and then incubated at 37˚C where 
appropriate. Following permeabilization of cells using Tween-20 (0.1% v/v in PBS) for 15 
min, samples were washed with PBS and centrifuged at 4000 rpm (4˚C). Removal of the 
supernatant was followed by addition of rabbit mAb LAMP-1 (1:400; Cell Signalling) for 1 h 
on ice. A further wash step was followed by adding both Alexa Fluor 488 goat anti human 
(1:200; Thermo Fisher) for detecting the ADC, and Alexa Fluor 568 goat anti rabbit (1:200; 
Thermo Fisher). Both secondary antibody incubations were performed on ice for 60 min. 
Nuclei were counterstained with Hoescht 33342 (Thermo Fisher), then cytospins of cell 
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samples were prepared and samples mounted in ProLong Gold anti-fade (Life Tech) and 
cover-slipped.  
In vitro and in vivo cross-linking determination  
Quantification of in vitro and in vivo cross-links was done by the single cell gel 
electrophoresis (comet) assay23 following the protocol and reagents previously described15.  
Assessment of ADCT-402 efficacy in in vivo models  
All animal studies were performed in facilities that are accredited by the Association for 
Assessment and Accreditation of Laboratory Animal Care (AAALAC), which assures 
compliance with accepted standards for the care and use of laboratory animals. Ramos, 
Daudi and WSU-DLCL2 xenografts were established in 8-10-week-old female Fox Chase 
SCID® (Charles River) by implanting 107 cells subcutaneously (s.c.) into their flanks. When 
group mean tumor volumes reached approximately 116-132 mm3, mice were randomly 
allocated into groups to receive test agent or vehicle. Each animal was euthanized when its 
tumor reached the endpoint volume or at study end. The time to endpoint (TTE) for analysis 
was calculated for each mouse by the following equation:  
TTE (days) = ([log 10 (endpoint volume– intercept*] / slope*) 
*of the line obtained by linear regression of a log-transformed tumor growth data set 
The logrank test was used to analyze the significance of differences between the TTE 
values of two groups.  
For the disseminated xenografts model, 5 x 106 Ramos cells and 1 x 107 NALM-6 cells were 
injected IV into the lateral tail vein of 5-7 week old, female Fox Chase SCID® and NOG 
(NOD.Cg-Prkdcscid Il2rgtm1Sug/JicTac) (Taconic) mice, respectively. Treatment with test 
compounds was initiated 7 days and 3 days after tumor inoculation in Ramos and NALM-6 
models, respectively. The day of death or euthanasia represented the TTE. Animals that did 
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not reach the endpoint were euthanized at the end of the study, and assigned a TTE value 
equal to the last study day. The logrank test was employed to determine the significance of 
the difference between the overall survival experiences (survival curves) of two groups, 
based on their TTE values. 
Immunohistochemistry of tumor xenografts and clinical samples sections 
Detection of phospho-histone H2A.X (Cell signalling #2577) and anti-PBD (Mouse 
monoclonal 14B3-B7; Spirogen) in murine FFPE tissue sections was performed using the 
Leica Bond Max automated staining platform. In brief, both primary antibodies were applied 
at 1:50 dilution for 30 min, following antigen retrieval of sections using Epitope retrieval 
solution 2 (Leica Biosystems). Peroxidase block (3-4% (v/v) H2O2) followed primary antibody 
application and antibody detection was performed using the Bond Polymer refine detection 
system (Leica Biosystems; DS9800). Detection of human CD19 (Leica NCL-CD19-163) in 
FFPE tissue sections of murine xenograft and human clinical samples was performed using 
the Roche BenchMark Ultra staining system. In brief, CD19 primary antibody was applied for 
30 min at 1:50 dilution following antigen retrieval of sections using CC1 solution (Ventana) 
for 60 min and a peroxidase blocking step. Detection of anti-CD19 antibody was performed 
using the Optiview DAB detection kit (# 760-700). 
Human lymphoma and leukaemia cases enrolled in this study (Table 1) were diagnosed 
according to the criteria of the WHO classification for haematological malignancies24 by an 
expert haematopathologist (TM) at UCLH. The immunohistochemical investigation was 
conducted according to the principles of the Helsinki declaration after approval of the internal 
review board, the National Research Ethics Service, Research Ethics Committee 4 (REC 
Reference number 09/H0715/64). 
Assessment of ADCT-402 pharmacokinetics (PK) 
All animal studies were performed at research facilities AAALAC accredited.  
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Male Crl:CD(SD) rats (Charles River Laboratories, UK) were dosed IV with ADCT-402. 
Blood was collected from tail veins at specified time points; serum was isolated and stored at 
-80°C.  
Male and female purpose bred Cynomolgus monkeys (Macaca fascicularis) were dosed IV 
with ADCT-402. Blood was collected from vena cephalica antebrachii or vena saphena at 
specific time points; serum was isolated and stored at -80°C.  
In rat and monkey serum, quantification of total antibody and ADC (DAR≥ 1) were 
determined using optimized ECLIA homogenous formats.  Calibration curves, QCs and 
study samples were diluted and mixed with a biotinylated anti-idiotypic antibody for both the 
total antibody and ADC measurements (biotinylated anti-PBD antibody for ADC in the 
monkey) and a Sulfo-tag labelled anti-idiotypic antibody for total antibody and a Sulfo-tag 
labelled anti-PBD antibody for the ADC (Sulfo-tag labelled anti-idiotypic antibody for ADC in 
the monkey) to allow complex formation.  The complex was added to streptavidin coated 
MSD plates and, following the addition of read buffer, the plate was read on the MSD 
QuickPlex Plate Reader (6000 Sector Imager (MSD) for the monkey). 
The determination of free SG3199 in cynomolgus monkey serum was performed by LC-
MS/MS and used deuterium-labelled SG3199 (SG3199-d10) as internal standard. Isolation 
of SG3199 (and spiked SG3199-d10) was performed by reduction with cyanoborohydride 
overnight and followed by off-line solid phase extraction using Oasis HLB 96-well µElution 
Plate, 30 µm Particle Size. The purified samples were analyzed using an AB Sciex Qtrap 
5500 LC-MS/MS system with a Zorbax SB-AQ Rapid Resolution HT (2.1 x 50 mm; 1.8 µm) 
column. 
The PK analysis was performed using Phoenix WinNonlin Version 6.2 with non-
compartmental analysis.  
 





Properties of ADCT-402 
ADCT-402 is composed of the humanized IgG1 antibody RB4v1.225, directed against human 
CD19, conjugated at interchain cysteines to tesirine using maleimide chemistry. Tesirine 
consists of a cathepsin-cleavable valine-alanine linker that releases the PBD dimer warhead 
SG319920 (Figure 1A). ADCT-402 is 96% monodisperse as determined by SEC (Figure 1B). 
DAR was determined to be 2.3 by RPLC (Figure 1C) and HIC (Figure 1D). 
 
Selective cytotoxicity of ADCT-402 in vitro 
The in vitro cytotoxicity of ADCT-402 was determined in a panel of eight CD19-expressing 
and two non-expressing cell lines. IC50 values were plotted against the cell surface CD19 
density for each cell line (Figure 2A), where a weak, yet significant negative correlation was 
observed (r value -0.7, p-value 0.024). In contrast, SG3199, the PBD dimer warhead 
component of ADCT-402, did not show any relationship between IC50 value and cell surface 
CD19 (r value -0.44, p-value 0.2), consistent with its non-target nature. Interestingly, the 
Granta-519 and NALM-6 cell lines, which were the most sensitive to SG3199, also showed 
the greatest sensitivity to the ADC. 
ADCT-402 Mechanism of Action 
CD19-expressing Ramos cells exposed to ADCT-402 (1 h at 4˚C) showed prominent cell 
surface binding (T=0, Figure 3A). On incubation at 37˚C, ADCT-402 showed internalization 
with some cell membrane labelling still evident at 1 h but also some co-localization with 
lysosomes. This co-localization increased at 2 and 4 h and no evidence of residual ADC 
staining was evident at 24 h suggesting complete lysosomal degradation.  
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DNA interstrand cross-linking was measured using a modification of the single cell gel 
electrophoresis (comet) assay. Cross-linking was expressed as the percentage decrease in 
Olive Tail Moment (OTM) compared to control irradiated cells. Following a 2-h exposure of 
Ramos cells to ADCT-402, the time course of cross-link formation is shown in Figure 3B. 
Cross-links form after an initial delay, reaching a peak at around 12 h, which persist up to 36 
h. In contrast, the free warhead SG3199 reached the peak of cross-linking during the initial 
2-h exposure. An equivalent concentration of a non-binding ADC did not show the formation 
of any cross-links. 
Ramos cells were treated with ADCT-402 for 1, 2, or 3 days, before transferring the media 
onto CD19-negative Karpas-299 cells, and incubating for 96 h. ADCT-402 conditioned 
medium elicited a bystander effect after 1 day of pre-treatment, as shown by a decrease in 
percentage survival in the conditioned medium-treated Karpas-299 cells compared to the 
non-conditioned medium (100% to 86%, Figure 3C, left panel). The effect was even greater 
after 2 or 3 days of pre-incubation in Ramos cells, as shown by a further decrease in 
percentage cell survival compared to the non-conditioned medium (80% and 65%, p = 
0.001). Conversely, conditioned medium from ADCT-402-treated, CD19-negative NCI-N87 
cells did not elicit any bystander effect when transferred onto Karpas-299 cells, regardless of 
pre-incubation time (Figure 3C, right panel). 
ADCT-402 In Vivo Efficacy 
ADCT-402 demonstrated dose-dependent anti-tumor activity against both s.c. and 
disseminated tumor models in vivo. In the s.c. Ramos xenograft, a single dose of ADCT-402 
at 0.33, 0.66 and 1 mg/kg induced dose-dependent anti-tumor activity and resulted in 5/10 
and 10/10 tumor-free survivors (TFS) at the 0.66 and 1 mg/kg doses, respectively, on day 60 
(Figure 4A). The resulting Kaplan-Meier survival curves show the dose-dependent extension 
of survival (log-rank test, p≤0.004 for each comparison, Supplementary Figure S1A). 
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In the same Ramos model, ADCT-402 was tested together with the CD19-targeted ADCs 
delivering maytansinoid (RB4v1.2-DM4, DAR=3.3) or auristatin (hBU12-mc-MMAF, 
DAR=4.2) warheads. ADCT-402 at a single dose of 1 mg/kg was remarkably superior to 
both the ADCs delivering tubulin binders at an equivalent single dose (Figure 4B). This 
superiority was maintained for ADCT-402 at 1 mg/kg even when the comparator ADCs were 
administered at higher doses with multiple administrations; 3.3 mg/kg, q4dx2 for RB4v1.2-
DM4 and 3 mg/kg, q4dx4 for hBU12-mc-MMAF, respectively (Figure 4B). The equivalent 
warhead amounts administered are given in Table S2 and Kaplan-Meier survival curves are 
shown in Figure S1B. ADCT-402 administered at 1 mg/kg induced a significant increase in 
survival compared to both comparator ADCs irrespective of dose level and frequency of 
administration (log-rank test, p≤0.001 for each comparison).  
In this same model, while a single dose of ADCT-402 at 1 mg/kg gave 10/10 TFS (Figure 
4C), fractionating the dose to 0.33 mg/kg given weekly x 3, or every 4 days x 3, did not 
achieve the same level of efficacy (Figure 4C). 
In a disseminated Ramos model, single dose ADCT-402 also showed significant extension 
of survival in comparison to controls (log-rank test, p≤0.001, Figure 4D) with 9/10 and 10/10 
animals surviving at day 91 for the 0.33 and 1 mg/kg groups, respectively, compared to no 
survival at day 19 for the vehicle and 1 mg/kg non-target ADC groups.  
ADCT-402 also showed dose-dependent activity in the CD19-expressing Daudi xenograft 
model (Figure 5A). At a single dose of 0.3 mg/kg all the animals achieved complete 
regression with 7/10 classified as TFS at the end of the study (day 73). Kaplan-Meier 
survival curves show the dose-dependent extension of survival (log-rank test, p≤0.001 for 
each comparison, Figure S2A).  
ADCT-402 was less effective at treating the WSU-DLCL2 xenograft model (Figure 5B). 
Although a clear dose-response was observed, the highest single dose used (1 mg/kg) only 
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produced a 30 day tumor growth delay. Yet, ADCT-402 resulted in significant, dose-
dependent extension of survival (log-rank test, p≤0.002 for each comparison, Figure S2B). 
In a second disseminated model (NALM-6), ADCT-402 at 0.33 and 1 mg/kg single dose 
produced a significant increase in survival compared to control ADC (log-rank test, p≤0.001, 
Figure 5C). At a dose of 1 mg/kg, 10/10 animals survived 90 days compared to only 21 days 
for the vehicle treated group.  
ADCT-402 Pharmacodynamics  
In mice with Ramos s.c. tumors, a single dose of ADCT-402 was administered at 0.3 or 1 
mg/kg (Figure S3). Twenty-four h after treatment, excised tumors showed a dose-related 
increase in staining intensity by an anti-PBD drug-linker antibody and a γ-H2AX antibody 
(Figure 6A). In contrast, tumors excised from mice treated with a non-targeted ADC, 
containing the same PBD dimer warhead, at 1 mg/kg did not show increased staining 
compared to vehicle control animals. CD19 staining remained high and homogeneous in all 
treatment groups (Figure 6A).  
Tumor samples were analysed for formation of DNA interstrand cross-linking and γ-H2AX 
foci. A significant increase in the level of γ-H2AX foci was observed in tumor cells at both 
ADCT-402 dose levels (Figure 6B), with no significant increase seen with the non-targeted 
ADC. DNA interstrand cross-linking in tumor cells, measured as the reduction in OTM, was 
also significant at both dose levels of ADCT-402 compared to vehicle or non-targeted ADC 
(Figure 6C). In contrast, no cross-linking was observed in PBMCs samples taken from the 
same mice (Figure S4). The selective targeting of ADCT-402 to human CD19-expressing 
tumor cells, resulting in the formation of DNA interstrand cross-links and an associated DNA 
damage response are therefore confirmed in vivo. 
ADCT-402 Pharmacokinetics in Rat and Cynomolgus Monkey 
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Quantitation of total or PBD-conjugated antibody was determined in rat serum following a 
single administration of 1.5 mg/kg to non-tumor bearing rats (Figure 7A). The half-life for 
total and PBD-conjugated antibody were 9.9 and 10.4 days, respectively (ADCT-402 does 
not cross-react with rat CD19) (Table S3), indicating typical IgG1 kinetics and excellent 
stability in vivo.  
Quantitation of total antibody, PBD-conjugated antibody and free SG3199 was also 
determined following administration of 0.6 mg/kg ADCT-402 on days 1 and 22 to 
cynomolgus monkeys (Figure 7B). The exposure profile of ADCT-402 indicates typical IgG1 
kinetics, a 14 day half-life (ADCT-402 does not cross-react with cynomolgus monkey CD19) 
(Table S3), and excellent stability in vivo.  




PBD-based ADCs are becoming established as important next-generation agents in the 
ADC arena. They exploit a completely different cellular mechanism to the first generation 
auristatin and maytansinoid tubulin inhibitors, and a different mode of DNA interaction to 
warheads such as calicheamicin26. Several PBD-containing ADCs have entered early phase 
clinical trials, falling into two distinct classes based on linker site attachment to the PBD 
dimer; C2 and N10. ADCT-402 is an example where the PBD warhead SG3199 is 
connected via its N10 position to a maleimidocaproyl valine- alanine dipeptide linker. This 
drug linker, tesirine, is the same as that in the clinical stage agents rovalpituzumab tesirine, 
ADCT-301, ADCT-502 and MEDI3726. As the N10-position imine is involved in covalent 
binding to DNA, linker attachment at this position produces a prodrug, adding a further level 
of safety over C2-linked agents. Consequently, attachment at the N10-imine requires a self-
immolative linker that becomes completely traceless following cleavage, as found in tesirine. 
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A CD19-directed ADC employing a first-generation PBD dimer with linker site attachment at 
the C2 position has recently been described27. 
ADCT-402 cytotoxicity showed a weak, yet significant negative linear correlation with cell 
surface CD19 target expression in a panel of ten hematological cancer cell lines (eight 
CD19-positive and two CD19-negative). This is in contrast to previously reported data for 
ADCT-301 and SGN-CD19B, which failed to show a clear relationship between sensitivity 
and antigen expression level15,27. In the case of ADCT-301, the limited number of CD25-
positive cell lines available all had high CD25 expression which may have been above a 
threshold for accurately determining cytotoxic sensitivity. In this study, all cell lines, including 
those negative for CD19 expression, were sensitive to the free warhead SG3199, consistent 
with the non-targeted delivery of the warhead alone. Some differential sensitivity, unrelated 
to CD19 expression, was observed for SG3199. Notably, the mantle cell lymphoma cell line 
Granta-519 and acute lymphoblastic leukemia cell line Nalm-6 were the most sensitive to 
both the ADC and the free warhead. Hematological cancer cell lines have previously been 
shown to be more sensitive, in general, to solid tumor cell lines28. In addition, certain 
hematological tumor types show exquisite sensitivity to PBD dimers which may predict target 
ADC cytotoxicity independently of CD19 expression above a threshold expression level. It 
has previously been shown that, for example, defects in homologous recombination repair or 
DNA repair protein ERCC1 confer increased sensitivity to PBD dimers29 suggesting a 
possible widening of therapeutic index in patients with tumors harbouring these defects, and 
indicates potential biomarkers of response. 
Evidence of rapid internalization of ADCT-402 is provided by the reduction in intensity of 
membrane immunofluorescence staining on CD19-expressing Ramos cells. Co-localization 
images suggest that processing of ADCT-402 is, at least in part, lysosomal. The time lag 
observed between the peak of DNA interstrand cross-link formation by ADCT-402 and by 
the naked warhead SG3199 reflects the time taken for internalization and cellular processing 
of the ADC compared with the readily diffusible PBD dimer. An important feature of the 
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highly cytotoxic cross-links produced is the minimal distortion of DNA which contribute to the 
lack of repair and consequent persistence over a 36-h period observed. 
If ADCT-402 is to be efficacious in lymphomas with heterogeneous CD19 expression, the 
existence of bystander toxicity of target-negative tumor cells is important. PBD warhead 
released from the target-positive cell would be expected to be diffusible in contrast to less 
permeable payloads such as MMAF. In medium transfer experiments, CD19-negative 
Karpas-299 cells were killed by a soluble factor released from ADCT-402-treated Ramos 
cells into the medium. This soluble factor is assumed to be SG3199 warhead, released by 
lysosomal cleavage of the val-ala dipeptide linker in ADCT-402 and the self-immolative 
cleavage of the residual linker stub on the PBD N10 imine, since we have shown that any 
transfer of intact ADC would be inactive against the CD19-negative cells. 
In vivo efficacy experiments show remarkable dose-related improvements in survival in both 
s.c. and disseminated models in three different tumor types (Burkitt’s lymphoma, ALL and 
DLBCL). Clear superiority is observed compared to comparator ADCs delivering tubulin 
inhibitor drugs, reflecting the increased potency of the PBD dimer warhead and the inherent 
sensitivity of haematological malignancies to critical DNA damage. It is clear that a single 
dose of ADCT-402 can selectively deliver sufficient cytotoxic agent, not only to induce 
growth delay, but also sustained tumor regression and in many cases tumor eradication. 
Interestingly, in the Ramos model, peak drug concentration (Cmax) appears to be necessary 
for complete response since administering the same total dose fractionated into three 
administrations (over two weeks or eight days) was significantly inferior, producing only 
tumor growth delay. This is in contrast to a recent report which observed similar anti-tumor 
activity against solid tumor xenografts in mice treated with single or fractionated dosing30.  
Anti-PBD payload antibody and anti-γ-H2AX staining confirmed the dose-dependent delivery 
of ADCT-402 to the target tumor xenograft. In addition, quantitative pharmacodynamic 
assessment of DNA cross-linking and γ-H2AX foci containing cells was achieved. γ-H2AX 
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has previously been shown to be a highly sensitive DNA damage response marker to DNA 
cross-linking agents including PBD dimers31,32, and both γ-H2AX immunofluorescence and 
measurement of DNA interstrand cross-links by comet assay have been used as 
pharmacodynamic assays in clinical trials of PBD dimer SG200017,32. Extrapolating from the 
in vivo data suggests that a threshold level of DNA interstrand cross-linking is required for 
tumor regression and eradication. This is consistent with previous data with CD25-targeting 
ADCT-30115 and also with the inferior fractionated dosing observed in this study. The 
absence of DNA cross-linking in mouse PBMCs supports the specificity of ADCT-402 in 
vivo. 
No change in expression of CD19 was observed in tumors 24 h post ADCT-402 
administration in vivo. An important consideration in the design of early phase clinical 
studies of ADCT-402 is the level and heterogeneity of target CD19 expression in patient 
tumors in the relevant R/R setting. To address this, we examined CD19 expression in a 
panel of matched (initial diagnosis and R/R) clinical samples (Table 1). High and 
homogeneous CD19 expression was observed across the whole panel of matched samples 
confirming maintenance of target antigen expression from initial diagnosis to relapse and 
confirming the excellent widespread nature of CD19 as an ideal target for clinical ADC 
development. 
ADCT-402 was found to have a favourable safety and PK profile with excellent stability in 
both rat and cynomolgus monkey. Taken together, these impressive pre-clinical data were 
used to support the rapid clinical testing of ADCT-402 in patients with CD19-expressing B-
cell malignancies. Phase I studies in both R/R NHL and R/R B-ALL are currently underway. 
Emerging clinical data confirm the potential of this therapy in targeting CD19-expressing B-
cell malignancies33-35.  
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Figure 1. Characterization of ADCT-402. A. Structure of ADCT-402. B. ADCT-402 
characterised by size exclusion chromatography (SEC). C. Reduced reverse phase liquid 
chromatography (RPLC) depicting reduced heavy and light chains of ADCT-402. D. 
Hydrophobic interaction chromatography (HIC) depicting DAR forms of ADCT-402. 
 
Figure 2. Correlation between in vitro cytotoxicity and cell surface CD19 density. A. 
IC50 values (mean of three independent determinations) of ADCT-402 against the named 
cell lines are plotted against the measured cell surface CD19 levels expressed as sites/cell. 
The line is the regression through all data points. B. The equivalent analysis performed for 
the naked PBD dimer warhead SG3199. Linear relationship between indicated variables was 
calculated by Pearson correlation coefficient r test. 
 
Figure 3. Mechanism of action of ADCT-402. A. Merged immunofluorescent images of 
CD19-positive, human Burkitt’s lymphoma-derived Ramos cells treated with 2 μg/ml ADCT-
402 for 1 h, washed and fixed after T=0, 1, 2, 4 or 24 h in medium at 37oC and stained with 
labelled anti-human IgG (green), anti-LAMP-1 (red) and Hoechst 33342 (blue) nuclear stain. 
Yellow indicates co-localization, with specific sites of co-localization indicated by stars. B. 
Time course of DNA interstrand cross-linking measured as the % reduction on Olive Tail 
Moment (OTM) in Ramos cells treated for 2 h with ADCT-402 (40 pM), SG3199 (10 pM) or a 
non-targeted ADC (40 pM) followed post-incubation in drug-free medium for the indicated 
time. Results are the mean ± s.d. from at least three independent experiments. C. 
Percentage viability of CD19-negative Karpas-299 cells after 96 h exposure to media 
transferred from ADCT-402-treated CD19-positive Ramos cells or CD19-negative NCI-N87 
cells for 1, 2 or 3 days. Statistical analysis was done with unpaired t test with Welch’s 
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correction (not assuming equal SD’s). The p values are two-tailed, * = p ≤ 0.05, ** = p ≤ 
0.01; ns = not significant. 
 
Figure 4. Comparative anti-tumor activity of ADCT-402 in the human CD19-expressing 
Burkitt’s lymphoma-derived Ramos model.  A. In vivo anti-tumor activity of ADCT-402 in 
s.c. implanted Ramos xenograft model. ADCT-402 was administered IV at a group mean 
tumor volume of 120 mm3 as a single dose at 0.33, 0.66 or 1 mg/kg.  B. In vivo anti-tumor 
activity of ADCT-402 in s.c. implanted Ramos xenograft model in comparison to ADCs 
RB4v1.2-DM4 and hBU12-mc-MMAF. All three ADCs were compared at a single dose of 1 
mg/kg and in addition RB4v1.2-DM4 and hBU12-mc-MMAF were also tested at 3.3 mg/kg, 
q4d x 2 and 3 mg/kg, q4d x 4, respectively. C. In vivo anti-tumor activity of ADCT-402 in s.c. 
implanted Ramos xenograft model where ADCT-402 was administered at a single dose of 1 
mg/kg or fractionated dosing of 0.33 mg/kg given either qwk x 3 or q4d x 3. Data in panels 
A-C are shown as mean ± standard error of the mean (SEM) from animal group sizes of 10 
mice. D. In vivo anti-tumor activity of ADCT-402 in a disseminated Ramos model. Kaplan-
Meier survival plots show percentage animal survival over 91 days in an experiment in which 
ADCT-402 was administered at a single dose of 0.33 mg/kg or 1 mg/kg in comparison to 
vehicle or non-targeting ADC administered as a single dose of 1 mg/kg (each group n = 10).   
 
Figure 5. Anti-tumor activity of ADCT-402 in a range of tumor models.  A. In vivo anti-
tumor activity of ADCT-402 in s.c. implanted CD19-expressing Burkitt’s lymphoma-derived 
Daudi xenograft model. ADCT-402 was administered IV at a group mean tumor volume of 
130 mm3 as a single dose at 0.1 mg/kg or 0.3 mg/kg. B. In vivo anti-tumor activity of ADCT-
402 in s.c. implanted CD19-expressing diffuse-large B-cell lymphoma-derived WSU-DLCL2 
xenograft model. ADCT-402 was administered IV at a group mean tumor volume of 120 mm3 
as a single dose at 0.3 mg/kg or 1 mg/kg. Data in panels A and B are the mean ± SEM from 
animal group sizes of 10 mice.  C. In vivo anti-tumor activity of ADCT-402 in a disseminated 
CD19-expressing acute-lymphoblastic leukemia-derived NALM-6 model. Kaplan-Meier 
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survival plots show percentage animal survival over 90 days in an experiment in which 
ADCT-402 was administered at a single dose of 0.33 mg/kg or 1 mg/kg in comparison to 
vehicle or non-targeting ADC administered as a single dose of 1 mg/kg (each group n = 10). 
Figure 6. Pharmacodynamic studies of ADCT-402. A. Representative scans of formalin 
fixed paraffin embedded (FFPE) Ramos xenograft tumor sections, obtained from vehicle- 
treated control mice or mice treated with 0.3 mg/kg and 1 mg/kg ADCT-402 or 1 mg/kg non-
targeting ADC and stained with an anti-CD19 antibody (top panels), anti-PBD linker antibody 
(middle panels) or an anti-γ-H2AX antibody (bottom panels). B. Histogram depicting % cells 
with γ-H2AX in tumor cell suspensions taken from Ramos xenograft tumors 24 h after 
injection with vehicle or 0.3 mg/kg or 1 mg/kg ADCT-402 or 1 mg/kg non-targeted ADC. Data 
represent the mean and standard deviation (SD) from three individual mice per data point.  
** = p ≤ 0.01, *** = p ≤ 0.001, ns = non-significant. C. Histogram depicting mean OTM in 
irradiated (I) or unirradiated (UI) tumor cell suspensions taken from Ramos xenograft tumors 
24 h after injection with vehicle or 0.3 mg/kg or 1 mg/kg ADCT-402 or 1 mg/kg non-targeted 
ADC. Data represent the mean and SD from three individual mice per data point. Statistical 
analysis was done with unpaired t-Test with Welch’s correction (not assuming equal SD’s). 
The P values are two-tailed; * = p ≤ 0.05, ** = p ≤ 0.01. 
Figure 7. Pharmacokinetics of ADCT-402 in rat and cynomolgus monkey. A. 
Quantitation of total antibody and PBD-conjugated ADCT-402 in rat serum from three 
individual Crl:CD(SD) rats treated with a single IV dose of 1.5 mg/kg. B. Quantitation of total 
antibody, PBD-conjugated antibody and free PBD dimer warhead SG3199 in cynomolgus 
monkey serum after IV administration of 0.6 mg/kg ADCT-402 on days 1 and 22. The results 
are mean ± SEM (n=2/5 male and 2/5 female).  
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